Should we stay or should we go? Recent insights on drug discontinuation in multiple sclerosis

Should we stay or should we go? Recent insights on drug discontinuation in multiple sclerosis

Abstract Background The decision to discontinue disease-modifying therapies (DMTs) in patients with multiple sclerosis (PwMS) is a critical clinical challenge. Historically, DMTs were discontinued due to side effects, treatment limitations, or progression to secondary progressive MS. However, advanc...

Full description

Saved in:
Bibliographic Details
Main Authors: Anne Mrochen, Sven G. Meuth, Steffen Pfeuffer
Format: Article
Language:English
Published: BMC 2025-04-01
Series:Neurological Research and Practice
Subjects:
Multiple sclerosis
Treatment discontinuation
Cardiovascular disease
Ageing
Online Access:https://doi.org/10.1186/s42466-025-00379-y
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s42466-025-00379-y

Similar Items